« Back
Home /
DR4 Antibody

DR4 Antibody

Item no.	PRS-1167-0.1mg
Manufacturer	ProSci
Amount	0.1 mg
Category	Antibodies Western Blot ELISA Immunofluorescence Immunocytochemistry Primary Antibodies
Type	Antibody Polyclonal
Format	Liquid
Applications	WB, IF, ICC, ELISA
Specific against	Human, Mouse, Rat
Host	Rabbit
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	DR4 Antibody: DR4, APO2, CD261, TRAILR1, TRAILR-1, DR4, Tumor necrosis factor receptor superfamily member 10A, Death receptor 4, TRAIL receptor 1
Available
Shipping	blue ice or RT
By Research Area	Apoptosis
Immunogen	Anti-DR4 antibody (1167) was raised against a peptide corresponding to 20 amino acids near the amino terminus of human DR4. The immunogen is located within the first 50 amino acids of DR4.
Applications	WB: 1-4 μ g/mL; ICC: 2 μ g/mL; IF: 5 μ g/mL. Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Specificity	DR4 antibody has no cross reaction to DR5.
Positive Control 1	Cat. No. 1202 - A431 Cell Lysate
Positive Control 2	Cat. No. 1203 - A549 Cell Lysate
Positive Control 3	Cat. No. 1224 - Daudi Cell Lysate
Positive Control 4	Cat. No. 1201 - HeLa Cell Lysate
Predicted Molecular Weight	Predicted: 50kD Observed: 55kD (Post-modification: 1 N-linked glycosylation)
Validation	KO Validation (Figure 1): Anti-DR4 antibodies (1167) specificity was further verified by DR4 specific knockout cell lysate. DR4 signal was detected in wild type cells, but not in the DR4 knockout cells. Independent Antibody Validation in Cell lines (Figure 2) shows similar DR4 expression profile in human cell lines detected by two independent anti-DR4 antibodies that recognize different epitopes, 1139 against C-terminus domain and 1167 against the N-terminus domain. DR4 proteins are detected in all the tested cell lines except CaCo-2 at different expression levels by the two independent antibodies. KD validation (Figure 6, 10): Anti-DR4 antibody specificity was further verified by DR4 specific siRNA knockdown. DR4 signal in SW480 and HeLa cells transfected with DR4 siRNAs was disrupted in comparison with that in cells transfected with control siRNAs.
Isoforms	Human DR4 has only 1 isoform (468aa, 50kD).
Purification	DR4 Antibody is Antibody is DEAE purified.
Clonality	Polyclonal
Isotype	IgG
Conjugate	Unconjugated
Buffer	DR4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration	1 mg/ml
Storage Conditions	DR4 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Related Products	Cat. No. 1167P – DR4 Peptide
Disclaimer	Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Modifications	None
Ncbi Official Symbol	TNFRSF10A
Accession #	AAC51226
Protein Gi #	1945072
Ncbi Gene Id #	8797
User Note	Optimal dilutions for each application to be determined by the researcher.
Ncbi Official Symbol	TNFRSF10A
Ncbi Official Full Name	tumor necrosis factor receptor superfamily, member 10a
Ncbi Organism	Homo sapiens
Swissprot #	O00220
Background	DR4 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-κ B activation in many tissues and cells.
Background References 1	Pan et al. Science 1997; 276:111-3
Background References 2	Wiley et al. Immunity 1995; 3:673-82
Background References 3	Pitti et al. J. Biol. Chem. 1996; 271:12687-90
Background References 4	Schneider et al. Immunity 1997; 7:831-6
Citation 1	Goda et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene. 2008 ; 27(24):3435-45. PMID: 18193086
Citation 2	Cantarella et al. Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype. Cell Death Dis. 2014 ; 5:e1331. PMID: 25032854
Citation 3	Ekmekcioglu et al. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathwaysvia MDA-7/IL-24. Cytokine. 2008; 43(1):34-44.PMID: 18511292
Citation 4	Devetzi et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep. 2016; 6:36532. PMID: 27827395
Citation 5	Horinaka et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene. 2005; 24(48):7180-9. PMID: 16007131
Citation 6	Malhi et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007; 56(8):1124-31. PMID: 17470478
Citation 7	Kalan et al. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep. 2017; 21(2):467-48 PMID: 29020632
Citation 8	Kurita et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene. 2010; 29(34):4848-58.PMID: 20562908
Citation 9	Potu et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. 2014; 5(14):5559-69. PMID: 24980819
Citation 10	Ashley et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer. 2008; 99(2):294-304. PMID: 18594532
Citation 11	Cazanave et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011; 286(45): 39336-48. PMID: 21941003
Citation 12	Song et al. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008; 283(36):25003-13.PMID: 18599488
Citation 13	Yoo et al. Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: development of a novel strategy for regional therapy. J Cell Biochem. 2007; 101(3):619-30. PMID: 17212362
Citation 14	Lauricella et al. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie. 2012; 94(2):287-99. PMID: 21835222
Citation 15	Cantarella et al. Protective effects of the sigma agonist Pre-084 in the rat retina. Br J Ophthalmol. 2007; 91(10):1382-4. PMID: 17522150
Citation 16	Lim et al. Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells. Oncol Lett. 2017; 13(5):3837-3844.PMID: 28529596
Citation 17	Taniguchi et al. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther. 2012; 11(10):2294-300.PMID: 22784708
Citation 18	Toriyama et al. A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. Mol Cancer Ther. 2016; 15(9):2066-75.PMID: 27406983
Citation 19	Lu et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011; 10(5):902-14.PMID: 21372226
Citation 20	Rizzardi etal. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas. Anticancer Res.2009; 29(4):1137-42.PMID: 19414356
1st Image Caption	Figure 1 KO Validation in HeLa Cells Loading: 10 μ g of HeLa WT cell lysates or DR4 KO cell lysates. Antibodies: DR4 1167 (1 μ g/mL) and beta-actin 3779 (1 μ g/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.
2nd Image Caption	Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines Loading: 15 μ g of lysates per lane.Antibodies: DR4 1139 (1 μ g/mL), DR4 1167 (4 μ g/mL), beta-actin (1 μ g/mL), and GAPDH (0.02 μ g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
3rd Image Caption	Figure 3 Western Blot Validation in Cell Lines Loading: 15 μ g of cell lysates per lane.Antibodies: DR4 1167 (4μ g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
4th Image Caption	Figure 4 Immunofluorescence Validation of DR4 in HeLa Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR4 with 1167 at 5 μ g/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on HeLa cells.
5th Image Caption	Figure 5 Immunocytochemistry Validation of DR4 in HeLa Cells Immunocytochemical analysis of HeLa cells using anti-DR4 antibody (1167) at 2 μ g/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
6th Image Caption	Figure 6 KD Validation in SW480 Cells (Goda et al., 2008) The expression of DR4 was knocked down via DR4 siRNA, 24 h latercells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies was disrupted. Dipyridamole up-regulated the expression of DR4.
7th Image Caption	Figure 7 Immunofluorescence Validation of DR4 in Rat Brain (Cantarella et al., 2014) DR4 protein expression detected by anti-DR4 antibodies was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a, d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.
8th Image Caption	Figure 8 Immunocytochemistry Validation of DR4 in Human Melanoma Cells (Ekmekcioglu et al., 2008) MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.
9th Image Caption	Figure 9 Immunohistochemistry Validation of DR4 in Human Colon Tumors (Devetzi et al., 2016) DR4 expression in human colon tumors detected by anti-DR4 antibodies. Strong immunoreactivity is shown for DR4 in T167. Moderate immunoreactivity is shown for DR4 in T187.
10th Image Caption	Figure 10 KD Validation in HeLa Cells (Horinaka et al., 2005) HeLa cells were transfected with DR4siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 μ M luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies. DR4 expression was markedly reduced after DR4 knockdown.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 0.1 mg

available

Delivery expected until 9/6/2024